Please login to the form below

Not currently logged in
Email:
Password:

overactive bladder

This page shows the latest overactive bladder news and features for those working in and with pharma, biotech and healthcare.

Allergan pushes on with Botox for depression

Allergan pushes on with Botox for depression

overactive in depression. ... Aside from its use as a wrinkle treatment Botox is already approved to treat various medical conditions, including chronic migraine, excessive sweating and overactive bladder among others, and is Allergan's

Latest news

  • Size matters? Size matters?

    Clinical trials are ongoing to test its application against overactive bladder and migraine.

  • Astellas sells dermatology unit to Leo for €675m Astellas sells dermatology unit to Leo for €675m

    The overarching aim is to prepare for the forthcoming patent expiries on big-selling drugs Vesicare (solifenacin succinate) for overactive bladder and cancer therapy Tarceva (erlotinib).

  • Eylea's UK launch earns Bayer PMEA success Eylea's UK launch earns Bayer PMEA success

    strategy. Other companies recognised in the category included Astellas, which was highly commended for its launch of overactive bladder treatment Betmiga, while Astellas and Shire were both finalists.

  • Germany’s IQWiG denies Astellas’ incontinence drug Germany’s IQWiG denies Astellas’ incontinence drug

    IQWiG, which assesses the cost-effectiveness of treatments for reimbursement in Germany, published an evaluation of Astellas' Betmiga (mirabegron) that does not recommend its use in the treatment of overactive bladder

  • Astellas uses animated bladder in campaign Astellas uses animated bladder in campaign

    Astellas uses animated bladder in campaign. Character in US advertisement for Myrbetriq constantly interrupts a woman with overactive bladder. ... The campaign is for overactive bladder (OAB) drug Myrbetriq shows an untreated bladder character constantly

More from news
Approximately 4 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new

  • Allergan and taking a specialised approach Allergan and taking a specialised approach

    In addition to migraine and adult spasticity, its approved indications include overactive bladder, muscle stiffness in elbow, wrist and fingers, muscle problems in the eye, crow's feet lines and severe

  • Interview: Kay Drake and Naoki Okamura, Astellas Interview: Kay Drake and Naoki Okamura, Astellas

    For example, we are a GCL in urology; we have Vesicare, which has 40 per cent market share in the overactive bladder (OAB) market. ... From an OAB perspective, we support the Bladder and Bowel Foundation here in the UK, which provides a patient advice

  • Interview: Ken Jones, Astellas Pharma Europe Interview: Ken Jones, Astellas Pharma Europe

    Urology is a key strategic area for Astellas and we have a strong pipeline in this therapy area; we are currently getting prepared with Mirabegron, a drug to treat overactive bladder,

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • emotive boosts health economics and outcomes research team

    His MSc project involved performing a health economic evaluation of the cost-effectiveness of different overactive bladder treatments available in the UK. ... The appointment of Trishal, with his specific expertise in visual science and overactive bladder

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics